BNP Paribas Financial Markets’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-13,662
| Closed | -$41.5K | – | 5646 |
|
|
2024
Q4 | $41.5K | Sell |
13,662
-10,728
| -44% | -$46.7K | ﹤0.01% | 4499 |
|
|
2024
Q3 | $127K | Sell |
24,390
-90,901
| -79% | -$452K | ﹤0.01% | 3402 |
|
|
2024
Q2 | $296K | Sell |
115,291
-96,404
| -46% | -$329K | ﹤0.01% | 2937 |
|
|
2024
Q1 | $1.04M | Buy |
211,695
+163,809
| +342% | +$970K | ﹤0.01% | 2475 |
|
|
2023
Q4 | $421K | Sell |
47,886
-94,416
| -66% | -$774K | ﹤0.01% | 2884 |
|
|
2023
Q3 | $1.63M | Sell |
142,302
-79,507
| -36% | -$1.53M | ﹤0.01% | 2009 |
|
|
2023
Q2 | $5.61M | Sell |
221,809
-83,372
| -27% | -$2.6M | 0.01% | 1178 |
|
|
2023
Q1 | $9.83M | Buy |
305,181
+82,382
| +37% | +$2.57M | 0.01% | 900 |
|
|
2022
Q4 | $4.11M | Buy |
+222,799
| New | +$5.1M | 0.01% | 1407 |
|
|
2022
Q3 | – | Sell |
-16,721
| Closed | -$231K | – | 5069 |
|
|
2022
Q2 | $231K | Buy |
16,721
+9,445
| +130% | +$145K | ﹤0.01% | 3021 |
|
|
2022
Q1 | $142K | Sell |
7,276
-8,689
| -54% | -$132K | ﹤0.01% | 3248 |
|
|
2021
Q4 | $261K | Sell |
15,965
-1,203
| -7% | -$20.1K | ﹤0.01% | 3289 |
|
|
2021
Q3 | $478K | Buy |
17,168
+8,443
| +97% | +$241K | ﹤0.01% | 2768 |
|
|
2021
Q2 | $259K | Sell |
8,725
-10,254
| -54% | -$296K | ﹤0.01% | 2802 |
|
|
2021
Q1 | $530K | Buy |
18,979
+6,810
| +56% | +$188K | ﹤0.01% | 2531 |
|
|
2020
Q4 | $345K | Sell |
12,169
-2,710
| -18% | -$70.2K | ﹤0.01% | 2639 |
|
|
2020
Q3 | $374K | Buy |
14,879
+12,526
| +532% | +$328K | ﹤0.01% | 2388 |
|
|
2020
Q2 | $57.5K | Sell |
2,353
-13,342
| -85% | -$263K | ﹤0.01% | 2984 |
|
|
2020
Q1 | $232K | Buy |
15,695
+10,434
| +198% | +$216K | ﹤0.01% | 2787 |
|
|
2019
Q4 | $85.4K | Sell |
5,261
-1,094
| -17% | -$17K | ﹤0.01% | 3361 |
|
|
2019
Q3 | $82.6K | Buy |
6,355
+2,087
| +49% | +$25.5K | ﹤0.01% | 3217 |
|
|
2019
Q2 | $55.4K | Sell |
4,268
-3,691
| -46% | -$46.5K | ﹤0.01% | 3359 |
|
|
2019
Q1 | $125K | Buy |
+7,959
| New | +$138K | ﹤0.01% | 2992 |
|
|
2018
Q4 | – | Sell |
-1,035
| Closed | -$25.7K | – | 4449 |
|
|
2018
Q3 | $25.7K | Hold |
1,035
| – | – | ﹤0.01% | 3313 |
|
|
2018
Q2 | $28.4K | Sell |
1,035
-4,494
| -81% | -$135K | ﹤0.01% | 3352 |
|
|
2018
Q1 | $170K | Buy |
5,529
+680
| +14% | +$21.9K | ﹤0.01% | 2892 |
|
|
2017
Q4 | $173K | Buy |
4,849
+2,696
| +125% | +$77.4K | ﹤0.01% | 3033 |
|
|
2017
Q3 | $59.3K | Sell |
2,153
-148
| -6% | -$3.59K | ﹤0.01% | 3062 |
|
|
2017
Q2 | $60.7K | Buy |
2,301
+2,174
| +1,712% | +$48.5K | ﹤0.01% | 3088 |
|
|
2017
Q1 | $2.64K | Sell |
127
-1,019
| -89% | -$20.9K | ﹤0.01% | 3463 |
|
|
2016
Q4 | $23.7K | Sell |
1,146
-411
| -26% | -$6.88K | ﹤0.01% | 3113 |
|
|
2016
Q3 | $25.2K | Buy |
1,557
+577
| +59% | +$8.38K | ﹤0.01% | 2766 |
|
|
2016
Q2 | $13.3K | Buy |
+980
| New | +$17.3K | ﹤0.01% | 2763 |
|
|
2016
Q1 | – | Sell |
-3,934
| Closed | -$134K | – | 3125 |
|
|
2015
Q4 | $134K | Buy |
3,934
+651
| +20% | +$22.6K | ﹤0.01% | 2153 |
|
|
2015
Q3 | $97.7K | Buy |
3,283
+1,981
| +152% | +$60.2K | ﹤0.01% | 2410 |
|
|
2015
Q2 | $41.6K | Buy |
1,302
+1,106
| +564% | +$28.4K | ﹤0.01% | 2600 |
|
|
2015
Q1 | $4.06K | Buy |
+196
| New | +$3.39K | ﹤0.01% | 3259 |
|
|
2014
Q4 | – | Sell |
-408
| Closed | -$7.89K | – | 3311 |
|
|
2014
Q3 | $7.89K | Buy |
+408
| New | +$10.6K | ﹤0.01% | 3697 |
|
Other funds holding RVNC
BNP Paribas Financial Markets's RVNC Position: Q1 2025 in Review
BNP Paribas Financial Markets sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,662 shares — an estimated $41.5K sold.
BNP Paribas Financial Markets first reported a position in RVNC in Q3 2014 and held it in 38 quarters. The position peaked at $9.83M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- BNP Paribas Financial Markets reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 13,662 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $41.5K.
- BNP Paribas Financial Markets first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 38 quarters.
- BNP Paribas Financial Markets's Revance Therapeutics, Inc. position peaked at $9.83M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2025, filed 14 May 2025.